{"schema":"sb.node.v1","id":"sb:e/b5ecab6445f962d4ca9c7209","kind":"entity","label":{"text":"gene therapy","locale":"en"},"identity":{"anchor":"label:en:gene therapy","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T19:00:35.865848+00:00","snapshot":"deploy b663cc8b34a8931137d702b8e11a6acd5fab341d"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":151,"separatePublishers":42,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"partial","share":0.371,"named":56,"of":151,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn from the former only","blind":["only 37% of the 151 documents measured name the subject in their own text; the rest mention it in passing, so standing.evidence.supporting overstates coverage about it"]}},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-03-12","to":"2026-10-10","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.252: about 75% of mentions carry no typed assertion"]}},"dimensions":{"domains":["biotech_pharma","auto"],"activeDays":40,"assertions":{"regulatory-approval":25,"acquisition":3,"utterance":3,"meeting-visit":2,"ipo-listing":1,"launch-release":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/86207def56e428e41077d885","kind":"observation","label":"The Hindu · 2026-10-08 · Crowdfunding helps seven-month-old SMA patient access ₹10 crore gene therapy","url":"https://www.thehindu.com/news/national/karnataka/crowdfunding-helps-seven-month-old-sma-patient-access-10-crore-gene-therapy/article71560366.ece"},{"id":"sb:o/982582f60f22549d3e3046d6","kind":"observation","label":"European Medical Journal · 2026-10-02 · Sanfilippo Syndrome Gene Therapy FDA Approved for Childhood Dementia","url":"https://www.emjreviews.com/neurology/news/sanfilippo-syndrome-gene-therapy-fda-approved-for-childhood-dementia/"},{"id":"sb:o/d8f19037acee879f87d51a9b","kind":"observation","label":"STAT News · 2026-10-01 · STAT+: Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy","url":"https://www.statnews.com/2026/10/01/huntingtons-disease-uniqure-drug-study-results-patients/?utm_campaign=rss"},{"id":"sb:o/ba261cb9d978d7b3d18c5864","kind":"observation","label":"Medical Daily · 2026-10-01 · Huntington's Gene Therapy Still Appears to Slow Daily Function Decline at Four Years, but Main Score Misses Significance","url":"https://www.medicaldaily.com/amt-130-four-year-data-huntingtons-families-fda-479348"},{"id":"sb:o/a5df37490858a1f31e08dee1","kind":"observation","label":"BioPharma Dive · 2026-09-30 · UniQure tumbles with latest data for Huntington’s gene therapy","url":"https://www.biopharmadive.com/news/uniqure-huntingtons-four-year-data-gene-therapy-results/831611/"},{"id":"sb:o/571065489097e385a382872e","kind":"observation","label":"Endpoints News · 2026-09-30 · UniQure sinks as Huntington's gene therapy appears to show waning benefit over time","url":"https://endpoints.news/uniqure-sinks-as-huntingtons-gene-therapy-appears-to-show-waning-benefit-over-time/"},{"id":"sb:o/f0dbb7dfba5aea95d0ecabc4","kind":"observation","label":"STAT News · 2026-09-29 · STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years","url":"https://www.statnews.com/2026/09/29/uniqure-huntingtons-gene-therapy-slows-disease-progression-four-years/?utm_campaign=rss"},{"id":"sb:o/955950fcba753481a8817ba2","kind":"observation","label":"Endpoints News · 2026-09-29 · Nonprofits' gene therapy for rare immune disease will cost $3.25M","url":"https://endpoints.news/nonprofits-gene-therapy-for-rare-immune-disease-will-cost-3-25-million/"},{"id":"sb:o/a5f00c5edbadee54b28baf0b","kind":"observation","label":"The Clinical Trial Vanguard · 2026-09-29 · 4D-150 Gene Therapy Enters Phase 3 Trial for Diabetic Macular Edema","url":"https://www.clinicaltrialvanguard.com/news/4d-150-gene-therapy-enters-phase-3-trial-for-diabetic-macular-edema/"},{"id":"sb:o/7ba20012f73040143fba67a5","kind":"observation","label":"Endpoints News · 2026-09-26 · Endpoints 11 2026 winner SonoThera has a new approach to non-viral gene therapy","url":"https://endpoints.news/endpoints-11-2026-winner-sonothera-has-a-new-approach-to-non-viral-gene-therapy/"}],"cursor":"c1.eyJpZCI6InNiOmUvYjVlY2FiNjQ0NWY5NjJkNGNhOWM3MjA5IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTEwVDE5OjAwOjM1Ljg2NTg0OCswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity whose own title or summary lead (the entity graph's test) names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":6,"byKind":{"co-mentioned":6},"items":[{"kind":"relation","label":"co-mentioned with fda (55 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/cef2aaff3653c8076a4ce687"},{"kind":"relation","label":"co-mentioned with ai (45 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/86734b67281b66023242defb"},{"kind":"relation","label":"co-mentioned with drug development (32 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c1ac59f24e1f7798a44e24cb"},{"kind":"relation","label":"co-mentioned with clinical trials (27 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/474b12d1be5b1877052ed2b0"},{"kind":"relation","label":"co-mentioned with clinical trial (25 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c6e6fdd15dc91800eaca581a"},{"kind":"relation","label":"co-mentioned with drug administration (20 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/64e52dc2fba3a34d97d0152c"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/b5ecab6445f962d4ca9c7209","mcp":"traverse {\"id\":\"sb:e/b5ecab6445f962d4ca9c7209\"}","page":"/entity/gene-therapy/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b5ecab6445f962d4ca9c7209\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b5ecab6445f962d4ca9c7209\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b5ecab6445f962d4ca9c7209\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/b5ecab6445f962d4ca9c7209\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}